Approach | Methodology | STEC detected | Advantages | Limitations | |
O157:H7 | Non-O157:H7 | ||||
Isolate-directed tests | Sorbitol MacConkey agar inoculation*[1] | Yes | No |
|
|
Chromogenic STEC agar inoculation[2] | Yes | Most |
|
| |
Shiga toxin antigen-detection | Overnight broth culture and antigen detection by enzyme immunoassay or lateral flow device[3] | Most | Yes |
|
|
Nucleic acid amplification tests | Genes encoding Shiga toxins 1 and 2 and DNA encoding the O157 lipopolysaccharide antigen | Yes | Yes |
|
|
SerologyΔ | Humoral immune response to O antigen[4] | Yes | Yes (limited at present to O121 and O145) |
|
|
HUS: hemolytic uremic syndrome.
* The sensitivity of sorbitol MacConkey agar screening can be improved by inoculating specimen on agar containing tellurite and cefixime.
¶ When the test platform fails to specify the presence or absence of Shiga toxin 2 (or its corresponding gene), ambiguous reports ("Shiga toxin is detected," "Shiga toxin 1 and/or 2 is detected," "Shiga toxin-producing E. coli are detected") are generated. In these situations, the physician cannot assess the likelihood that the patient will develop HUS, because it is not known if a high-risk STEC (ie, one that produces Shiga toxin 2) underlies the positive antigen or toxin gene signal. If the submitted stool was from a patient with nonbloody diarrhea, the risk of a high-risk STEC being present is lower. If E. coli O157:H7 was sought and was negative, the risk is also lower (at least in North America where E. coli O157:H7 remains the predominant high-risk STEC). However, these are not absolute criteria, because high-risk non-O157:H7 STEC can cause HUS, and high-risk STEC O157 and non-O157 can cause nonbloody diarrhea.
Δ These tests are not commercially available outside Argentina.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟